Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine ...

The National Institutes of Health are the world’s largest funder of medical research, distributing $35 billion in in grants ...

In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.

the NIH's acting director Dr. Matthew Memoli also requested information last week about the funding that supports mRNA ...

Pfizer PFE-0.38%decrease; red down pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

In vaccines, Pfizer plans to start a Phase 3 study for ... The company also expects to launch a Phase 3 trial for its C. difficile vaccine. The internal medicine segment remains a priority ...

The trial met its primary endpoint in the estrogen receptor ... including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.

Vaccine hesitancy and higher rates of school vaccine exemptions increases the risk of outbreaks of preventable diseases, ...

Ongoing clinical trials to develop a lung cancer ... since they partnered with Pfizer to develop the first COVID-19 vaccine,” Lester said. The mRNA technology is “the infrastructure needed ...